Brian Ladle, MD, PhD
Pediatric Medical OncologyPediatric Hematology OncologySarcoma and Connective Tissue Medical Oncology
Highlights
Age Groups Seen
- Infant 0-2
- Child 3-12
- Adolescent 13-17
- Young Adult 18-25
Languages
- English
In-Network Plans
View All Accepted Plans (12)Gender
MaleJohns Hopkins Affiliations:
- Johns Hopkins School of Medicine Faculty
About Brian Ladle
Primary Academic Title
Assistant Professor of Oncology
Johns Hopkins Physician
Background
Dr. Brian Ladle is a pediatric cancer specialist in Baltimore, caring for patients with pediatric sarcoma, neuroblastoma, and other rare solid tumors. In addition to seeing patients, Dr. Ladle leads clinical research studies and his laboratory research program to develop new therapies for pediatric cancers.
Dr. Ladle received his undergraduate degree in molecular biology from Brigham Young University. He earned his M.D. and Ph.D. degrees at the Johns Hopkins University School of Medicine. He completed his residency at Cincinnati Children’s Hospital Medical Center and performed a fellowship in pediatric hematology and oncology at Johns Hopkins and the National Institutes of Health. Dr. Ladle joined the Johns Hopkins faculty in 2013.
Dr. Ladle's research program focuses on translational immunology, with the goal of developing novel immunotherapies for the treatment of pediatric malignancies. His lab currently focuses on augmenting anti-tumor immune responses to solid tumors such as osteosarcoma, Ewing sarcoma, and rhabdomyosarcoma.
He is a member of the American Association for Cancer Research, the American Society for Pediatric Hematology/Oncology, the American Society of Clinical Oncology and the Children's Oncology Group.
Dr. Ladle is passionate about ensuring all patients receive cutting-edge, compassionate care as a member of the exceptional care team provided for each pediatric oncology patient and their family.
Centers and Institutes
Clinical Trials Summary
Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma
Find a Clinical Trial
View all trials by this principal investigator.
Recent News Articles and Media Coverage
Five Mothers Unite in $1.5 Million Ewing Sarcoma Grant, St. Baldrick's Foundation (August 29, 2025)
Additional Academic Titles
Assistant Professor of Pediatrics
Research Interests
Immunotherapy, Pediatric sarcomas, Translational immunology
Research Summary
Dr. Ladle is a practicing pediatric oncologist and translational immunology researcher who has the goal of developing novel immunotherapies for the treatment of pediatric malignancies. His research seeks to understand mechanisms of immune tolerance in pediatric sarcomas and developing successful combination immunotherapies that will successfully treat sarcoma patients. He is working on translational projects combining immunotherapy with chemotherapy, epigenetic modifying agents and innate immune system adjuvants. Dr. Ladle has extensive expertise in immunology techniques – including both mouse and in vitro cell culture, multi-color flow cytometry and molecular techniques.
Selected Publications
A.M. Ercolini and B.H. Ladle (co-first authorship), E.A. Manning, L. Pfannenstiel, T.D. Armstrong, J.P.H. Machiels, J.G. Bieler, L.A. Emens, R.T. Reilly, E.M. Jaffee. “Recruitment of latent pools of high avidity CD8+ T cells to the anti-tumor immune response.” The Journal of Experimental Medicine. 2005 May 16;201(10):1591-602.
D.T. Le and B.H. Ladle (co-first authorship), T. Lee, V. Weiss, X. Yao, A. Leubner, T.D. Armstrong, E.M. Jaffee. “CD8+ Foxp3+ tumor infiltrating lymphocytes accumulate in the context of an effective anti-tumor response.” International Journal of Cancer. 2011 Aug 1;129(3):636-47.
R.M. Thomas, C.J. Gamper, B.H. Ladle, J.D. Powell, A.D. Wells. “De novo DNA methylation is required to restrict T helper lineage plasticity.” Journal of Biological Chemistry. 2012 Jun 29;287(27):22900-9
S. Murata, B.H. Ladle, P.S. Kim, E.R. Lutz, M.E. Wolpoe, S.E. Ivie, H.M. Smith, T.D. Armstrong, L.A. Emens, E.M. Jaffee, R.T. Reilly. “OX40 Costimulation Synergizes with GM-CSF Whole-cell Vaccination to Overcome Established CD8+ T cell Tolerance to an Endogenous Tumor Antigen.” The Journal of Immunology. 2006 Jan. 15; 176(2):974-83.
Courses & Syllabi
Graduate Immunology Course, Lecturer, Johns Hopkins University School of Medicine, 1/1/18
Honors
- $1000 Presentation Award, Immuno-Oncology Young Investigator's Forum, 1/1/15
- John G. Rangos, Sr. Medal of Honor in Creative Thinking, 1/1/12
- Optimist International Research Fellow, Sidney Kimmel Comprehensive Cancer Center, 1/1/11
- Blackfan Research Award, Cincinnati Children's Hospital Medical Center, 1/1/10
- Turock Young Scientist Award, Johns Hopkins Institute of Basic Biomedical Sciences, 1/1/03
Memberships
- American Association for Cancer Research
- American Society for Pediatric Hematology/Oncology
- Children's Oncology Group
- American Society of Clinical Oncology
Professional Activities
- Member, Protocol Committee, National Pediatric Cancer Foundation, 2018
Locations
- Johns Hopkins Children's Center
- 1800 Orleans Street, Bloomberg 11N, Baltimore, MD 21287
- Get Directions
- phone: 410-955-8751
- fax: 410-614-1802
Expertise
Education
- Fellowship: National Institutes of Health, Pediatric Hematology-Oncology, 2014
- Fellowship: Johns Hopkins University School of Medicine, Pediatric Hematology-Oncology, 2013
- Residency: Cincinnati Children's Hospital, Pediatrics, 2010
- Medical Education: Johns Hopkins University School of Medicine, MD PhD, 2007
Board Certifications
- Pediatric Hematology-Oncology: American Board of Pediatrics, 2015
- Pediatrics: American Board of Pediatrics, 2011
Insurance
- Aetna
- CareFirst
- Cigna
- First Health
- Geisinger Health Plan
- HealthSmart/Accel
- Johns Hopkins Health Plans
- MultiPlan
- Pennsylvania's Preferred Health Networks (PPHN)
- Point Comfort Underwriters
- Private Healthcare Systems (PHCS)
- Veteran Affairs Community Care Network (Optum-VACCN)